Insider · CIK 0001741285

ZDRAVESKI ZORAN

Reports to the SEC for 2 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001741285

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-01	TCRXTScan Therapeutics, Inc.A Award	See Remarks	AAward	+300K sh	—	—	304,716
2026-01-20	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+350K sh	—	—	350,000
2025-01-03	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+250K sh	—	—	250,000
2024-08-23	TCRXTScan Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+54.9K sh	$4.85	+$266K	67,111
2024-08-23	TCRXTScan Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+25K sh	$3.27	+$81.8K	92,111
2024-08-23	TCRXTScan Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+13.1K sh	$1.81	+$23.8K	105,236
2024-08-23	TCRXTScan Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+64.2K sh	$2.49	+$160K	169,402
2024-08-23	TCRXTScan Therapeutics, Inc.S Sale	See Remarks	SSale	−165K sh	$5.78	−$952K	4,716
2024-08-23	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−54.9K sh	—	—	30,105
2024-08-23	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−25K sh	—	—	25,000
2024-08-23	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−13.1K sh	—	—	21,875
2024-08-23	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−64.2K sh	—	—	365,834
2024-01-12	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+52.5K sh	—	—	52,500
2023-06-13	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+430K sh	—	—	430,000
2023-02-02	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+35K sh	—	—	35,000
2022-07-25	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+50K sh	—	—	50,000
2022-01-18	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+85K sh	—	—	85,000
2021-09-23	TCRXTScan Therapeutics, Inc.P Purchase	See Remarks	PPurchase	+4,716 sh	$7.48	+$35.3K	4,716
2021-09-07	TCRXTScan Therapeutics, Inc. · Stock Option (right to buy)A Award	See Remarks	AAward	+150K sh	—	—	150,000
2021-02-11	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+67.7K sh	—	—	67,700
2020-02-10	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+60K sh	—	—	60,000
2019-12-24	DNTHDianthus Therapeutics, Inc. /DE/S Sale	See Remarks	SSale	−7,902 sh	$16.00	−$126K	128,009
2019-12-24	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	See Remarks	MExercise/Conversion	+820 sh	$7.71	+$6,322.2	140,912
2019-12-24	DNTHDianthus Therapeutics, Inc. /DE/S Sale	See Remarks	SSale	−7,902 sh	$16.00	−$126K	133,010
2019-12-24	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−820 sh	—	—	16,856
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/S Sale	See Remarks	SSale	−4,181 sh	$16.03	−$67K	135,911
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	See Remarks	MExercise/Conversion	+9 sh	$7.71	+$69.39	140,101
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	See Remarks	MExercise/Conversion	+4,172 sh	$9.49	+$39.6K	144,273
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/S Sale	See Remarks	SSale	−4,181 sh	$16.03	−$67K	140,092
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−4,172 sh	—	—	129,342
2019-12-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−9 sh	—	—	17,676
2019-02-05	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	See Remarks	AAward	+80K sh	—	—	80,000
2018-06-25	DNTHDianthus Therapeutics, Inc. /DE/C Conversion	See Remarks	CConversion	+4,643 sh	—	—	140,092
2018-06-25	DNTHDianthus Therapeutics, Inc. /DE/ · Series C Preferred StockC Conversion	See Remarks	CConversion	−12K sh	—	—	0

Recent filings

Accepted (ET)
Oct 24
ZDRAVESKI ZORAN0001193125-26-412518
SEC(opens sec.gov)
Jan 224
ZDRAVESKI ZORAN0001193125-26-019674
SEC(opens sec.gov)
Feb 114
ZDRAVESKI ZORAN0000950170-25-018131
SEC(opens sec.gov)
Aug 274
ZDRAVESKI ZORAN0000950170-24-101161
SEC(opens sec.gov)
Jun 154
ZDRAVESKI ZORAN0000899243-23-015632
SEC(opens sec.gov)
Feb 64
ZDRAVESKI ZORAN0000899243-23-004064
SEC(opens sec.gov)
Jul 274
ZDRAVESKI ZORAN0000899243-22-026847
SEC(opens sec.gov)
Jan 204
ZDRAVESKI ZORAN0000899243-22-002646
SEC(opens sec.gov)
Sep 274
ZDRAVESKI ZORAN0000899243-21-037802
SEC(opens sec.gov)
Sep 94
ZDRAVESKI ZORAN0000899243-21-035470
SEC(opens sec.gov)
Feb 164
ZDRAVESKI ZORAN0000899243-21-006713
SEC(opens sec.gov)

Companies

Address

C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET

WALTHAM, MA, 02451